Article by David Brown, Lift News
Quebec-based medical cannabis producer Hydropothecary has announced they are expanding their voluntary product recall from earlier this year to include 19 lots of cannabis products. Health Canada is considering this a Type III recall, or ‘not likely to cause any adverse health consequences’.
The expanded recall is the result of what the company says was an extensive internal investigation of the facility and all products in storage. The company tested 281 samples taken from every harvest from their facility, and the results of the investigation have been supplied to Health Canada. The company initially issued a stop-sale in early May, previous to the recall.
The Hydropothecary says they have contacted all clients affected by the recall as well as the regulator, and that the company is implementing new measures to help prevent any future use of an unregulated product.
The results of their internal testing show trace amounts of myclobutanil between 0.01 parts per million and 0.13 parts per million on the 19 recalled lots. A Type III recall is categorized by Health Canada as “a situation in which the use of, or exposure to a product is not likely to cause any adverse health consequences.” Myclobutanil is not an approved pesticide for use on cannabis in Canada.
The Hydropothecary press release states that their own internal investigation suggests the myclobutanil was applied to some plants by a former employee, and that no such applications occurred after internal changes resulting from a recall last fall for using the wrong brand of a sulfur product.